Intravenous formate or oral methanol as a formate pro-drug increase formate availability to tumor-infiltrating lymphocytes and augment anti-PD-1 efficacy in MC38, aligning with the 1 C-metabolic constraint of effector T cells [52]. This evidence concerns the gene PDCD1 and neoplasm.